Y mAbs Therapeutics (YMAB) — Cash Flow-to-Debt Ratio
Y mAbs Therapeutics (YMAB) has a Cash Flow-to-Debt Ratio of 0.06x as of June 2025, meaning its operating cash flow of $1.65 Million could theoretically repay 0% of its total liabilities ($29.72 Million) in one year. See YMAB FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Y mAbs Therapeutics Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Y mAbs Therapeutics across 9 annual periods. Also explore how fast is Y mAbs Therapeutics growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Y mAbs Therapeutics (2016–2024)
Year-by-year debt coverage analysis for Y mAbs Therapeutics. For market capitalisation and broader financial context, see Y mAbs Therapeutics (YMAB) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.56x | $-15.71 Million | $27.90 Million | ▲ +44.4% |
| 2023 | -1.01x | $-27.23 Million | $26.88 Million | ▲ +57.0% |
| 2022 | -2.36x | $-75.92 Million | $32.23 Million | ▲ +25.0% |
| 2021 | -3.14x | $-102.56 Million | $32.68 Million | ▲ +9.8% |
| 2020 | -3.48x | $-91.23 Million | $26.21 Million | ▲ +17.3% |
| 2019 | -4.21x | $-73.50 Million | $17.46 Million | ▼ -16.3% |
| 2018 | -3.62x | $-41.23 Million | $11.40 Million | ▼ -127.4% |
| 2017 | -1.59x | $-15.87 Million | $9.97 Million | ▲ +25.9% |
| 2016 | -2.15x | $-11.17 Million | $5.20 Million | — |